Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSAgE study: Dose-reduced Chemotherapy for Advanced Colorectal Cancer in Older Patients
2023-506115-17-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine, fluorouracil, oxaliplatin and folinic acid in metastatic colon cancer (mCRC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
capecitabinefluorouraciloxaliplatinfolinic acid
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2023-506115-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506115-17-00.